Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrative Multi-OMICs Identifies Therapeutic Response Biomarkers and Confirms Fidelity of Clinically Annotated, Serially Passaged Patient-Derived Xenografts Established from Primary and Metastatic Pediatric and AYA Solid Tumors.
Pandya PH, Jannu AJ, Bijangi-Vishehsaraei K, Dobrota E, Bailey BJ, Barghi F, Shannon HE, Riyahi N, Damayanti NP, Young C, Malko R, Justice R, Albright E, Sandusky GE, Wurtz LD, Collier CD, Marshall MS, Gallagher RI, Wulfkuhle JD, Petricoin EF, Coy K, Trowbridge M, Sinn AL, Renbarger JL, Ferguson MJ, Huang K, Zhang J, Saadatzadeh MR, Pollok KE. Pandya PH, et al. Among authors: barghi f. Cancers (Basel). 2022 Dec 30;15(1):259. doi: 10.3390/cancers15010259. Cancers (Basel). 2022. PMID: 36612255 Free PMC article.
Systems Biology Approach Identifies Prognostic Signatures of Poor Overall Survival and Guides the Prioritization of Novel BET-CHK1 Combination Therapy for Osteosarcoma.
Pandya PH, Cheng L, Saadatzadeh MR, Bijangi-Vishehsaraei K, Tang S, Sinn AL, Trowbridge MA, Coy KL, Bailey BJ, Young CN, Ding J, Dobrota EA, Dyer S, Elmi A, Thompson Q, Barghi F, Shultz J, Albright EA, Shannon HE, Murray ME, Marshall MS, Ferguson MJ, Bertrand TE, Wurtz LD, Batra S, Li L, Renbarger JL, Pollok KE. Pandya PH, et al. Among authors: barghi f. Cancers (Basel). 2020 Aug 26;12(9):2426. doi: 10.3390/cancers12092426. Cancers (Basel). 2020. PMID: 32859084 Free PMC article.
Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells.
Momeny M, Eyvani H, Barghi F, Ghaffari SH, Javadikooshesh S, Hassanvand Jamadi R, Esmaeili F, Alishahi Z, Zaghal A, Bashash D, Samani FS, Ghaffari P, Dehpour AR, Tavangar SM, Alimoghaddam K, Ghavamzadeh A. Momeny M, et al. Among authors: barghi f. Anticancer Drugs. 2018 Nov;29(10):1011-1020. doi: 10.1097/CAD.0000000000000681. Anticancer Drugs. 2018. PMID: 30096128
Blockade of nuclear factor-κB (NF-κB) pathway inhibits growth and induces apoptosis in chemoresistant ovarian carcinoma cells.
Momeny M, Yousefi H, Eyvani H, Moghaddaskho F, Salehi A, Esmaeili F, Alishahi Z, Barghi F, Vaezijoze S, Shamsaiegahkani S, Zarrinrad G, Sankanian G, Sabourinejad Z, Hamzehlou S, Bashash D, Aboutorabi ES, Ghaffari P, Dehpour AR, Tavangar SM, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Among authors: barghi f. Int J Biochem Cell Biol. 2018 Jun;99:1-9. doi: 10.1016/j.biocel.2018.03.015. Epub 2018 Mar 19. Int J Biochem Cell Biol. 2018. PMID: 29567488
Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M, Zarrinrad G, Moghaddaskho F, Poursheikhani A, Sankanian G, Zaghal A, Mirshahvaladi S, Esmaeili F, Eyvani H, Barghi F, Sabourinejad Z, Alishahi Z, Yousefi H, Ghasemi R, Dardaei L, Bashash D, Chahardouli B, Dehpour AR, Tavakkoly-Bazzaz J, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Among authors: barghi f. Sci Rep. 2017 Jun 23;7(1):4204. doi: 10.1038/s41598-017-04147-0. Sci Rep. 2017. PMID: 28646172 Free PMC article.
Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells.
Momeny M, Sabourinejad Z, Zarrinrad G, Moghaddaskho F, Eyvani H, Yousefi H, Mirshahvaladi S, Poursani EM, Barghi F, Poursheikhani A, Dardaei L, Bashash D, Ghazi-Khansari M, Tavangar SM, Dehpour AR, Yaghmaie M, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Among authors: barghi f. Sci Rep. 2017 Apr 6;7:45954. doi: 10.1038/srep45954. Sci Rep. 2017. PMID: 28383032 Free PMC article.
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Momeny M, Moghaddaskho F, Gortany NK, Yousefi H, Sabourinejad Z, Zarrinrad G, Mirshahvaladi S, Eyvani H, Barghi F, Ahmadinia L, Ghazi-Khansari M, Dehpour AR, Amanpour S, Tavangar SM, Dardaei L, Emami AH, Alimoghaddam K, Ghavamzadeh A, Ghaffari SH. Momeny M, et al. Among authors: barghi f. Sci Rep. 2017 Mar 13;7:44075. doi: 10.1038/srep44075. Sci Rep. 2017. PMID: 28287096 Free PMC article.